TWI796353B - 丙酮酸激酶調節劑及其用途 - Google Patents
丙酮酸激酶調節劑及其用途 Download PDFInfo
- Publication number
- TWI796353B TWI796353B TW107128431A TW107128431A TWI796353B TW I796353 B TWI796353 B TW I796353B TW 107128431 A TW107128431 A TW 107128431A TW 107128431 A TW107128431 A TW 107128431A TW I796353 B TWI796353 B TW I796353B
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- alkyl
- methyl
- instance
- protecting group
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/CN2017/097496 | 2017-08-15 | ||
| CN2017097496 | 2017-08-15 | ||
| US201862673533P | 2018-05-18 | 2018-05-18 | |
| US201862673526P | 2018-05-18 | 2018-05-18 | |
| US62/673,526 | 2018-05-18 | ||
| US62/673,533 | 2018-05-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201919631A TW201919631A (zh) | 2019-06-01 |
| TWI796353B true TWI796353B (zh) | 2023-03-21 |
Family
ID=63524352
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107128431A TWI796353B (zh) | 2017-08-15 | 2018-08-15 | 丙酮酸激酶調節劑及其用途 |
| TW107128429A TWI790271B (zh) | 2017-08-15 | 2018-08-15 | 用於治療血液病症之丙酮酸激酶活化劑 |
| TW111135803A TWI823580B (zh) | 2017-08-15 | 2018-08-15 | 用於治療血液病症之丙酮酸激酶活化劑 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107128429A TWI790271B (zh) | 2017-08-15 | 2018-08-15 | 用於治療血液病症之丙酮酸激酶活化劑 |
| TW111135803A TWI823580B (zh) | 2017-08-15 | 2018-08-15 | 用於治療血液病症之丙酮酸激酶活化劑 |
Country Status (34)
| Country | Link |
|---|---|
| US (8) | US11464775B2 (https=) |
| EP (4) | EP3668881B1 (https=) |
| JP (5) | JP7301040B2 (https=) |
| KR (3) | KR102642408B1 (https=) |
| CN (3) | CN111032045B (https=) |
| AU (4) | AU2018316588B2 (https=) |
| BR (1) | BR112020003254A2 (https=) |
| CA (1) | CA3072455A1 (https=) |
| CL (1) | CL2020000375A1 (https=) |
| CO (2) | CO2020002959A2 (https=) |
| CR (1) | CR20200123A (https=) |
| CY (1) | CY1124953T1 (https=) |
| DK (2) | DK3668513T3 (https=) |
| EC (1) | ECSP20018487A (https=) |
| ES (3) | ES2905100T3 (https=) |
| FI (1) | FI3668512T3 (https=) |
| HR (2) | HRP20220039T1 (https=) |
| HU (2) | HUE061910T2 (https=) |
| IL (3) | IL272599B (https=) |
| LT (2) | LT3668513T (https=) |
| MD (1) | MD3668513T2 (https=) |
| MX (2) | MX2020001833A (https=) |
| MY (1) | MY204421A (https=) |
| PE (1) | PE20200724A1 (https=) |
| PH (1) | PH12020500343B1 (https=) |
| PL (2) | PL3668513T3 (https=) |
| PT (2) | PT3668513T (https=) |
| RS (2) | RS62871B1 (https=) |
| SG (2) | SG11202001262QA (https=) |
| SI (2) | SI3668512T1 (https=) |
| SM (2) | SMT202200023T1 (https=) |
| TW (3) | TWI796353B (https=) |
| UA (1) | UA126292C2 (https=) |
| WO (3) | WO2019035864A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| TWI796353B (zh) * | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| EP3697354A4 (en) | 2017-10-20 | 2021-06-30 | The Regents of The University of Michigan | EYE DISEASE COMPOSITIONS AND METHODS |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
| WO2020262419A1 (ja) * | 2019-06-26 | 2020-12-30 | 日産化学株式会社 | 電荷輸送性ワニス |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| EP4185293A4 (en) * | 2020-07-21 | 2025-01-15 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE |
| CN112490502B (zh) * | 2020-12-04 | 2022-01-21 | 广州天赐高新材料股份有限公司 | 一种电解液及锂二次电池 |
| US11566030B2 (en) | 2021-02-08 | 2023-01-31 | Global Blood Therapeutics, Inc. | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023052783A1 (en) * | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| IL312679A (en) * | 2021-11-16 | 2024-07-01 | Agios Pharmaceuticals Inc | Compounds for the treatment of anemia associated with MDS and other conditions |
| CN116159061A (zh) * | 2023-03-09 | 2023-05-26 | 上海市第十人民医院 | 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用 |
| EP4671102A1 (en) | 2023-03-28 | 2025-12-31 | Honda Motor Co., Ltd. | METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS |
| TW202509043A (zh) | 2023-05-15 | 2025-03-01 | 美商阿吉歐斯製藥公司 | ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式 |
| KR20260035223A (ko) * | 2023-07-05 | 2026-03-12 | 아지오스 파마슈티컬스 아이엔씨. | 피루브산 키나아제 활성화제의 합성 |
| TW202539675A (zh) | 2024-03-27 | 2025-10-16 | 美商阿吉歐斯製藥公司 | Ｐｋ活化劑在治療鐮狀細胞疾病中之用途 |
| WO2026076363A1 (en) | 2024-10-04 | 2026-04-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012151448A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405635A (en) | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
| US4883914A (en) | 1987-08-17 | 1989-11-28 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds useful as herbicidal agents |
| CA2380644A1 (en) | 1999-07-30 | 2001-02-08 | Basf Aktiengesellschaft | 2-pyrazolin-5-ones |
| CA2381581A1 (en) | 1999-09-04 | 2001-03-15 | Astrazeneca Ab | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2933983B1 (fr) * | 2008-07-15 | 2010-08-27 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| MX2011000843A (es) * | 2008-07-23 | 2011-04-11 | Vertex Pharma | Inhibidores de pirazolopiridin cinasa triciclicos. |
| EP2334673A1 (en) * | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| WO2010042867A2 (en) | 2008-10-09 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| CA2758071C (en) * | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| KR101861883B1 (ko) | 2010-12-06 | 2018-05-28 | 글락소 그룹 리미티드 | Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물 |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CN103608016A (zh) * | 2011-05-03 | 2014-02-26 | 安吉奥斯医药品有限公司 | 丙酮酸激酶激活剂在治疗中的用途 |
| WO2012151450A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| SMT202400081T1 (it) * | 2011-05-03 | 2024-03-13 | Agios Pharmaceuticals Inc | Attivatori della piruvato chinasi per uso in terapia |
| HK1198443A1 (en) * | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| WO2013056153A1 (en) * | 2011-10-13 | 2013-04-18 | Kung Charles | Activators of pyruvate kinase m2 and methods of treating disease |
| US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| EA032007B1 (ru) | 2012-11-08 | 2019-03-29 | Аджиос Фармасьютикалз, Инк. | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 |
| WO2014118135A1 (en) * | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| EP2968323A4 (en) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| AR112475A1 (es) | 2017-08-15 | 2019-10-30 | Agios Pharmaceuticals Inc | Moduladores de piruvato quinasas y uso de los mismos |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
-
2018
- 2018-08-15 TW TW107128431A patent/TWI796353B/zh active
- 2018-08-15 MX MX2020001833A patent/MX2020001833A/es unknown
- 2018-08-15 RS RS20220003A patent/RS62871B1/sr unknown
- 2018-08-15 PL PL18779068T patent/PL3668513T3/pl unknown
- 2018-08-15 RS RS20230354A patent/RS64221B1/sr unknown
- 2018-08-15 SM SM20220023T patent/SMT202200023T1/it unknown
- 2018-08-15 PE PE2020000245A patent/PE20200724A1/es unknown
- 2018-08-15 CN CN201880053315.9A patent/CN111032045B/zh active Active
- 2018-08-15 EP EP18766063.4A patent/EP3668881B1/en active Active
- 2018-08-15 EP EP18766400.8A patent/EP3668512B1/en active Active
- 2018-08-15 SM SM20230146T patent/SMT202300146T1/it unknown
- 2018-08-15 MY MYPI2020000757A patent/MY204421A/en unknown
- 2018-08-15 US US16/639,086 patent/US11464775B2/en active Active
- 2018-08-15 FI FIEP18766400.8T patent/FI3668512T3/fi active
- 2018-08-15 CA CA3072455A patent/CA3072455A1/en active Pending
- 2018-08-15 ES ES18779068T patent/ES2905100T3/es active Active
- 2018-08-15 US US16/639,075 patent/US11364240B2/en active Active
- 2018-08-15 SG SG11202001262QA patent/SG11202001262QA/en unknown
- 2018-08-15 PL PL18766400.8T patent/PL3668512T3/pl unknown
- 2018-08-15 PT PT187790688T patent/PT3668513T/pt unknown
- 2018-08-15 PT PT187664008T patent/PT3668512T/pt unknown
- 2018-08-15 AU AU2018316588A patent/AU2018316588B2/en active Active
- 2018-08-15 KR KR1020207007346A patent/KR102642408B1/ko active Active
- 2018-08-15 HU HUE18766400A patent/HUE061910T2/hu unknown
- 2018-08-15 AU AU2018316587A patent/AU2018316587B2/en active Active
- 2018-08-15 DK DK18779068.8T patent/DK3668513T3/da active
- 2018-08-15 SG SG11202001353PA patent/SG11202001353PA/en unknown
- 2018-08-15 EP EP21207073.4A patent/EP4026838A1/en not_active Withdrawn
- 2018-08-15 WO PCT/US2018/000128 patent/WO2019035864A1/en not_active Ceased
- 2018-08-15 CN CN202310962497.4A patent/CN117186119B/zh active Active
- 2018-08-15 CR CR20200123A patent/CR20200123A/es unknown
- 2018-08-15 BR BR112020003254-9A patent/BR112020003254A2/pt not_active Application Discontinuation
- 2018-08-15 SI SI201830914T patent/SI3668512T1/sl unknown
- 2018-08-15 CN CN201880053325.2A patent/CN111032046B/zh active Active
- 2018-08-15 WO PCT/US2018/000127 patent/WO2019035863A1/en not_active Ceased
- 2018-08-15 TW TW107128429A patent/TWI790271B/zh active
- 2018-08-15 PH PH1/2020/500343A patent/PH12020500343B1/en unknown
- 2018-08-15 KR KR1020207007344A patent/KR102717594B1/ko active Active
- 2018-08-15 LT LTEPPCT/US2018/000128T patent/LT3668513T/lt unknown
- 2018-08-15 JP JP2020508455A patent/JP7301040B2/ja active Active
- 2018-08-15 HR HRP20220039TT patent/HRP20220039T1/hr unknown
- 2018-08-15 IL IL272599A patent/IL272599B/en unknown
- 2018-08-15 UA UAA202001747A patent/UA126292C2/uk unknown
- 2018-08-15 US US16/639,081 patent/US11590132B2/en active Active
- 2018-08-15 DK DK18766400.8T patent/DK3668512T3/da active
- 2018-08-15 LT LTEPPCT/US2018/000129T patent/LT3668512T/lt unknown
- 2018-08-15 JP JP2020508498A patent/JP7275107B2/ja active Active
- 2018-08-15 ES ES18766063T patent/ES2966825T3/es active Active
- 2018-08-15 EP EP18779068.8A patent/EP3668513B1/en active Active
- 2018-08-15 WO PCT/US2018/000129 patent/WO2019035865A1/en not_active Ceased
- 2018-08-15 HR HRP20230452TT patent/HRP20230452T1/hr unknown
- 2018-08-15 MX MX2020001832A patent/MX2020001832A/es unknown
- 2018-08-15 MD MDE20200663T patent/MD3668513T2/ro unknown
- 2018-08-15 SI SI201830558T patent/SI3668513T1/sl unknown
- 2018-08-15 ES ES18766400T patent/ES2944545T3/es active Active
- 2018-08-15 HU HUE18779068A patent/HUE057178T2/hu unknown
- 2018-08-15 TW TW111135803A patent/TWI823580B/zh active
- 2018-08-15 KR KR1020237028222A patent/KR102764124B1/ko active Active
-
2020
- 2020-02-11 IL IL272597A patent/IL272597B/en unknown
- 2020-02-13 CL CL2020000375A patent/CL2020000375A1/es unknown
- 2020-03-12 CO CONC2020/0002959A patent/CO2020002959A2/es unknown
- 2020-03-12 CO CONC2020/0002961A patent/CO2020002961A2/es unknown
- 2020-03-13 EC ECSENADI202018487A patent/ECSP20018487A/es unknown
- 2020-11-19 US US16/952,257 patent/US11040036B2/en active Active
-
2022
- 2022-01-18 CY CY20221100039T patent/CY1124953T1/el unknown
- 2022-01-27 US US17/586,777 patent/US11872225B2/en active Active
- 2022-04-26 IL IL292530A patent/IL292530B2/en unknown
- 2022-05-16 US US17/744,806 patent/US11957680B2/en active Active
- 2022-12-14 JP JP2022199462A patent/JP2023027276A/ja active Pending
-
2023
- 2023-01-18 JP JP2023005925A patent/JP7530453B2/ja active Active
- 2023-01-20 US US18/099,311 patent/US12133853B2/en active Active
- 2023-05-03 AU AU2023202772A patent/AU2023202772B2/en active Active
-
2024
- 2024-07-26 JP JP2024121066A patent/JP2024147805A/ja active Pending
- 2024-08-16 AU AU2024205818A patent/AU2024205818A1/en not_active Abandoned
- 2024-09-12 US US18/882,884 patent/US20250144093A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012151448A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
Non-Patent Citations (2)
| Title |
|---|
| Clin Cancer Res; 18(20) October 15, 2012，Mayumi Tamada1 , Makoto Suematsu2,4, and Hideyuki Saya ，Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells |
| EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 28, no. 1，SEVKI ADEM ΕΤ AL: "Pyruvate kinase activators as a therapy target: a patent review 2011-2017";Clin Cancer Res; 18(20) October 15, 2012，Mayumi Tamada1 , Makoto Suematsu2,4, and Hideyuki Saya ，Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI796353B (zh) | 丙酮酸激酶調節劑及其用途 | |
| RU2537945C2 (ru) | Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб | |
| EP2763976B1 (en) | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors | |
| US20220127267A1 (en) | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders | |
| CA2767097A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| CN112236429A (zh) | 用作ii型irak抑制剂的杂芳基化合物及其用途 | |
| JP2022510380A (ja) | チロシンキナーゼ阻害剤、組成及びその方法 | |
| TW202325288A (zh) | 新穎化合物 | |
| RU2797518C2 (ru) | Модуляторы пируваткиназы и их применение | |
| HK40030322B (en) | Pyruvate kinase modulators and use thereof | |
| HK40030322A (en) | Pyruvate kinase modulators and use thereof | |
| HK40077435A (en) | Pyruvate kinase activators for use in treating blood disorders | |
| HK40043591A (en) | Heteroaryl compounds as type ii irak inhibitors and uses thereof | |
| HK40030323B (en) | Pyruvate kinase activators for use in treating blood disorders |